Sickle Cell Disease Laboratory

The sickle cell disease laboratory has a primary aim of advancing curative therapies for sickle cell disease such as allogeneic hematopoietic stem cell transplantation and autologous hematopoietic stem cell gene therapy approaches. The lab focuses on the immunobiology of hematopoietic cell engraftment, virus-specific immunity restoration following transplantation, and identifying the best hematopoietic stem cell source for gene modification to treat patients during early childhood prior to the development of irreversible complications of sickle cell disease.

Key publications:

Outcomes following posttransplant viral-specific T-cell therapy in patients with sickle cell disease.
Kinoshita H, Mandava M, Jensen-Wachspress MA, Lang H, Joy E, Tanna J, McCann CD, O'Brien S, Burnett S, Shibli A, Hoq F, Bhatia M, Hanley PJ, Dávila Saldaña BJ, Mahadeo KM, Bollard CM, Keller MD, Abraham AA.Blood Adv. 2022 Dec 14:bloodadvances.2022008219. doi: 10.1182/bloodadvances.2022008219. Online ahead of print.

Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease.
Abraham AA, Lang H, Meier ER, Nickel RS, Dean M, Lawal N, Speller-Brown B, Wang Y, Kean L, Bollard CM.Pediatr Blood Cancer. 2019 May;66(5):e27601. doi: 10.1002/pbc.27601. Epub 2019 Jan 4.PMID: 30609269

Cellular therapy for sickle cell disease.
Abraham A, Jacobsohn DA, Bollard CM.Cytotherapy. 2016 Nov;18(11):1360-1369. doi: 10.1016/j.jcyt.2016.06.011. Epub 2016 Jul 14.PMID: 27421743